Serdar Karakas, Sezai Yilmaz, Volkan Ince, Sami Akbulut, Yasin Dalda, Ayse Nur Akatli, Aysegul Sagir Kahraman, Ramazan Kutlu, Brian Irving Carr
{"title":"符合米兰标准且肝功能保存良好的肝细胞癌患者肝切除与活体供肝移植的比较。","authors":"Serdar Karakas, Sezai Yilmaz, Volkan Ince, Sami Akbulut, Yasin Dalda, Ayse Nur Akatli, Aysegul Sagir Kahraman, Ramazan Kutlu, Brian Irving Carr","doi":"10.14744/hf.2023.2023.0005","DOIUrl":null,"url":null,"abstract":"<p><strong>Background and aim: </strong>Liver resection (LR) and liver transplantation (LT) are curative treatments for hepatocellular carcinoma (HCC). The main purpose of this study was to compare the survival of LR and LDLT in patients with HCC within the Milan criteria.</p><p><strong>Materials and methods: </strong>The results of the LR (n=67) and LDLT (n=391) groups were compared for overall survival (OS) and disease-free survival (DFS). Twenty-six of the HCCs in the LRs met the Milan and Child A criteria. Also, 200 of the HCC patients in the LDLTs met the Milan criteria, of which 70 also met the Child A criteria.</p><p><strong>Results: </strong>Early mortality was higher in the LDLT group (13.9% vs 1.47%; p=0.003). The 5-year OS was higher in the LDLTs than the LRs, but not statistically significant (84.6% vs 74.2%; p=0.287). However, 5-year DFS was better in the LDLT group (96.8% vs 64.3%; p<0.001). When the LRs (n=26) and the LDLTs (n=70) that met both Milan and Child A criteria were compared, 5-year OS was similar (81.4% vs 74.2%; p=0.512), but DFS was better in the LDLTs (98.6% vs 64.3%; p<0.001).</p><p><strong>Conclusion: </strong>LR can be justified as the first-line treatment for HCC patients who meet Milan and Child A criteria in terms of early mortality and OS.</p>","PeriodicalId":29722,"journal":{"name":"Hepatology Forum","volume":null,"pages":null},"PeriodicalIF":1.2000,"publicationDate":"2023-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/27/76/hf-4-047.PMC10209977.pdf","citationCount":"1","resultStr":"{\"title\":\"Comparison of liver resection and living donor liver transplantation in patients with hepatocellular carcinoma within Milan criteria and well-preserved liver function.\",\"authors\":\"Serdar Karakas, Sezai Yilmaz, Volkan Ince, Sami Akbulut, Yasin Dalda, Ayse Nur Akatli, Aysegul Sagir Kahraman, Ramazan Kutlu, Brian Irving Carr\",\"doi\":\"10.14744/hf.2023.2023.0005\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><strong>Background and aim: </strong>Liver resection (LR) and liver transplantation (LT) are curative treatments for hepatocellular carcinoma (HCC). The main purpose of this study was to compare the survival of LR and LDLT in patients with HCC within the Milan criteria.</p><p><strong>Materials and methods: </strong>The results of the LR (n=67) and LDLT (n=391) groups were compared for overall survival (OS) and disease-free survival (DFS). Twenty-six of the HCCs in the LRs met the Milan and Child A criteria. Also, 200 of the HCC patients in the LDLTs met the Milan criteria, of which 70 also met the Child A criteria.</p><p><strong>Results: </strong>Early mortality was higher in the LDLT group (13.9% vs 1.47%; p=0.003). The 5-year OS was higher in the LDLTs than the LRs, but not statistically significant (84.6% vs 74.2%; p=0.287). However, 5-year DFS was better in the LDLT group (96.8% vs 64.3%; p<0.001). When the LRs (n=26) and the LDLTs (n=70) that met both Milan and Child A criteria were compared, 5-year OS was similar (81.4% vs 74.2%; p=0.512), but DFS was better in the LDLTs (98.6% vs 64.3%; p<0.001).</p><p><strong>Conclusion: </strong>LR can be justified as the first-line treatment for HCC patients who meet Milan and Child A criteria in terms of early mortality and OS.</p>\",\"PeriodicalId\":29722,\"journal\":{\"name\":\"Hepatology Forum\",\"volume\":null,\"pages\":null},\"PeriodicalIF\":1.2000,\"publicationDate\":\"2023-03-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/27/76/hf-4-047.PMC10209977.pdf\",\"citationCount\":\"1\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Hepatology Forum\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.14744/hf.2023.2023.0005\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q4\",\"JCRName\":\"GASTROENTEROLOGY & HEPATOLOGY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Hepatology Forum","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.14744/hf.2023.2023.0005","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q4","JCRName":"GASTROENTEROLOGY & HEPATOLOGY","Score":null,"Total":0}
引用次数: 1
摘要
背景与目的:肝切除(LR)和肝移植(LT)是治疗肝细胞癌(HCC)的有效方法。本研究的主要目的是比较米兰标准下肝细胞癌患者LR和LDLT的生存率。材料与方法:比较LR组(n=67)和LDLT组(n=391)的总生存期(OS)和无病生存期(DFS)。LRs中的26个hcc符合米兰标准和儿童A标准。此外，ldlt中200例HCC患者符合米兰标准，其中70例也符合Child A标准。结果:LDLT组早期死亡率较高(13.9% vs 1.47%;p = 0.003)。ldlt患者的5年OS高于LRs患者，但无统计学意义(84.6% vs 74.2%;p = 0.287)。然而，LDLT组的5年DFS更好(96.8% vs 64.3%;结论:在早期死亡率和OS方面，LR可作为满足Milan和Child A标准的HCC患者的一线治疗。
Comparison of liver resection and living donor liver transplantation in patients with hepatocellular carcinoma within Milan criteria and well-preserved liver function.
Background and aim: Liver resection (LR) and liver transplantation (LT) are curative treatments for hepatocellular carcinoma (HCC). The main purpose of this study was to compare the survival of LR and LDLT in patients with HCC within the Milan criteria.
Materials and methods: The results of the LR (n=67) and LDLT (n=391) groups were compared for overall survival (OS) and disease-free survival (DFS). Twenty-six of the HCCs in the LRs met the Milan and Child A criteria. Also, 200 of the HCC patients in the LDLTs met the Milan criteria, of which 70 also met the Child A criteria.
Results: Early mortality was higher in the LDLT group (13.9% vs 1.47%; p=0.003). The 5-year OS was higher in the LDLTs than the LRs, but not statistically significant (84.6% vs 74.2%; p=0.287). However, 5-year DFS was better in the LDLT group (96.8% vs 64.3%; p<0.001). When the LRs (n=26) and the LDLTs (n=70) that met both Milan and Child A criteria were compared, 5-year OS was similar (81.4% vs 74.2%; p=0.512), but DFS was better in the LDLTs (98.6% vs 64.3%; p<0.001).
Conclusion: LR can be justified as the first-line treatment for HCC patients who meet Milan and Child A criteria in terms of early mortality and OS.
求助内容：
应助结果提醒方式：
京公网安备 11010802042870号
